<DOC>
	<DOCNO>NCT02841800</DOCNO>
	<brief_summary>Only small proportion patient biliary obstruction cause hepatopancreatobiliary malignancy suitable surgical resection . Therefore , patient malignant biliary obstruction need palliation obstructive jaundice relieve symptom prevent life threaten complication biliary sepsis . The endoscopic percutaneous/transhepatic route , endoscopic retrograde cholangiopancreatography ( ERCP ) percutaneous transhepatic cholangiography ( PTC ) , stent accept approach relief jaundice malignant biliary obstruction . Improvement bilirubin level also essential palliative chemotherapy consider patient . However , tumor ingrowth still remain major cause obstruction . In trial , investigator use HabibTM EndoHPB ( EMcision Ltd. , UK ) catheter use endobiliary radiofrequency ablation ( RFA ) treatment form neoadjuvant therapy hepatopancreatobiliary adenocarcinoma .</brief_summary>
	<brief_title>Intra-luminal Radiofrequency Ablation Inoperable Malignant Biliary Stenosis</brief_title>
	<detailed_description>The HabibTM EndoHPB ( EMcision Ltd. , UK ) catheter use endobiliary radiofrequency ablation ( RFA ) treatment endoscopic bipolar catheter design ablate tissue malignant tumor within luminal structure . HabibTM EndoHPB Food Drug Administration ( FDA ) European Conformity approval indication . It also approve Ministry Health Welfare 2016 . In study , investigator perform intra-luminal RFA 20 inoperable patient malignant biliary stenosis . HabibTM EndoHPB deploy via endoscopic retrograde cholangiopancreatography ( ERCP ) route . By use radiofrequency energy heat tissue duct prior insertion stent , surround tissue becomes coagulate may delay tumor growth time stent lumen becomes occlude . If stent occlusion occur participant follow period , participant reassess investigation use determine cause stent occlusion whether appropriate repeat RFA treatment . The aim detect improvement survival safety treat patient compare patient receive palliative treatment record literature .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Phenobarbital</mesh_term>
	<criteria>Patients must meet follow inclusion criterion eligible study : 1 . 20 Years old . 2 . The diagnosis hepatopancreaticobiliary cancer pathologic proven , diagnosis hepatopancreaticobiliary cancer make pathology / cytology accord American Association Study Liver Diseases ( AASLD ) ( 2010 ) diagnostic criterion . 3 . Participant unsuitable surgical resection . Criteria unresectability base metastatic disease locally advance . 4 . Eastern Cooperative Oncology Group ( ECOG ) score 01 . 5 . American Society Anaesthesiologists ( ASA ) score ≤ 3 . 6 . Karnofsky score &gt; 30 . 7 . Jaundice ( bilirubin level 10 mg/dL ) . Alanine transaminase ( ALT ) aspartate transaminase ( AST ) &lt; 5 x upper limit normal . 8 . Prothrombin time ( PT ) international normalize ratio ( INR ) ≦ 2.0 . Platelet count ≥ 100 K/Μl . 9 . Expected survive 3 month . Patients present follow enrol study : 1 . Under age 20 year old . 2 . Women pregnant woman childbearing potential use acceptable method contraception . 3 . Known history human immunodeficiency virus ( HIV ) infection . 4 . Patients serious systemic disease good fit test . 5 . Tumor occupy 50 % liver parenchyma 6 . Any active metal implant device ( eg Pacemaker ) . 7 . Guidewire pas bile duct stenosis .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>radiofrequency ablation</keyword>
	<keyword>malignant biliary stenosis</keyword>
</DOC>